Revvity Inc. stock extends gains on strong year-to-date performance

Published on 09/06/2026 at 20:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revvity Inc. stock has climbed sharply over the past year, with the latest market data showing the share price near its 52-week high and a solid year-to-date gain that keeps the life sciences group on investors radar.

Labor mit Wissenschaftlerin an Sequenziergerät und Reagenzflaschen — Fotorealistisches Life-Sciences-Labor zeigt Revvity Inc. (ISIN US76155R1086) mit automatisiertem Sequenziergerät und Reagenzien, Illustration mit AI erstellt.

Revvity Inc. stock (ISIN US76155R1086) is trading close to its recent highs, with a last quoted level of about 130.24 US dollars as of September 4, 2026 according to MarketBeat. Year-to-date, the share has gained 34.5 percent from its starting point, underscoring how Revvity has rewarded investors in 2026 so far.

Stock performance and valuation signals

The latest detailed quote data compiled by Yahoo Finance shows a previous close of 118.86 US dollars for Revvity stock, with the day’s trading range between 113.93 and 118.26 US dollars and a 52-week range of 97.32 to 129.50 US dollars.

That 52-week span means that even the 118.86 US-dollar close from the latest trading session sits just below the upper end of the range, leaving the stock less than 10 percent from its 129.50 US-dollar 52-week high according to the same data. The narrow distance between the current level and the high signals that the market continues to price Revvity as a relatively strong performer within its life sciences peer group.

Analyst consensus points to limited upside

Analyst sentiment toward Revvity Inc. remains cautiously constructive but not euphoric. According to the consensus overview at MarketBeat, the company holds an average rating score of 2.24 on their scale, based on four buy ratings, thirteen hold ratings and no sell ratings.

MarketBeat also reports a consensus price target of 114.77 US dollars for Revvity stock, which at the time of their snapshot represented about 11.9 percent downside from the then-current trading level of 130.24 US dollars. For investors, this quantified gap between the market price and the analyst target illustrates that many analysts see the valuation as rich after the 34.5 percent share price increase since the start of the period captured in that analysis.

Go deeper

More data and background on Revvity Inc.

Further quotes, historical charts and corporate disclosures on Revvity Inc. can be accessed via the topic overview for the ISIN US76155R1086 and the company’s own investor information.

Revvity Inc. on ad-hoc-news.de Investor Relations

Business profile and product focus

Revvity Inc., created from the transformation of the former PerkinElmer life sciences and diagnostics operations, positions itself as a science and technology company focused on precision diagnostics, discovery and analytical solutions across pharmaceutical, biotech and academic markets. Its portfolio includes instruments, reagents and software that support research and clinical workflows in genomics, cell biology, diagnostics and laboratory automation.

One representative part of the business is its genomics and molecular diagnostics offering, which includes assay kits and platforms designed to detect genetic variants and molecular markers in research and clinical samples. These solutions aim to help laboratories improve throughput and accuracy when screening for inherited conditions or analyzing gene expression, making Revvity a relevant partner for hospitals and research centers that seek to modernize their laboratory infrastructure.

Stock level and investor takeaways

Based on the most recent comprehensive quote from MarketBeat as of September 4, 2026, Revvity stock traded at 130.24 US dollars on the New York Stock Exchange, with the consensus analyst target at 114.77 US dollars and a reported 34.5 percent increase over the tracked period. Combined with the 52-week high of 129.50 US dollars from Yahoo Finance data, the figures underline that the share price currently embeds a strong run-up and sits near its upper trading band, a setup that investors should factor into their assessment of future risk and reward.